StockData
Disc Medicine, Inc. logo

Disc Medicine, Inc. (IRON) stock

IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$76.57−0.02 (-0.03%)

Close on Nov 17, 2026Market cap $2.94BP/E –Yield –

Disc Medicine r&d expenses

Research and development expenses are spending on new products and technology.

Disc Medicine's R&D Expenses for the twelve months ending Jun 30, 2026 was $189.40M, up 53.3% year over year. For fiscal 2025 it was $170.64M, up 76.5% from the year before. The highest annual figure on record is $170.64M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$170.64M+76.5%
FY2024Dec 31, 2024$96.67M+39.6%
FY2023Dec 31, 2023$69.26M+107.1%
FY2022Dec 31, 2022$33.44M+32.8%
FY2021Dec 31, 2021$25.17M-10.6%
FY2020Dec 31, 2020$28.17M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$46.93M+1.3%
Q1 FY2026Mar 31, 2026$45.90M+65.3%
Q4 FY2025Dec 31, 2025$46.22M+86.4%
Q3 FY2025Sep 30, 2025$50.33M+103.9%
Q2 FY2025Jun 30, 2025$46.32M+97.2%
Q1 FY2025Mar 31, 2025$27.76M+17.1%
Q4 FY2024Dec 31, 2024$24.80M+9.9%
Q3 FY2024Sep 30, 2024$24.69M+71.2%
Q2 FY2024Jun 30, 2024$23.49M+94.1%
Q1 FY2024Mar 31, 2024$23.70M+17.5%
Q4 FY2023Dec 31, 2023$22.57M+125.3%
Q3 FY2023Sep 30, 2023$14.42M+82.8%
Q2 FY2023Jun 30, 2023$12.10M+56.9%
Q1 FY2023Mar 31, 2023$20.18M+158.0%
Q4 FY2022Dec 31, 2022$10.02M-20.7%
Q3 FY2022Sep 30, 2022$7.89M-41.4%
Q2 FY2022Jun 30, 2022$7.71M-28.9%
Q1 FY2022Mar 31, 2022$7.82M-33.6%
Q4 FY2021Dec 31, 2021$12.63M+64.1%
Q3 FY2021Sep 30, 2021$13.46M+100.0%
Q2 FY2021Jun 30, 2021$10.84M+96.1%
Q1 FY2021Mar 31, 2021$11.79M+43.4%
Q4 FY2020Dec 31, 2020$7.70M–
Q3 FY2020Sep 30, 2020$6.73M–
Q2 FY2020Jun 30, 2020$5.53M–
Q1 FY2020Mar 31, 2020$8.22M–

More Disc Medicine figures

See a number that looks wrong?